# Multi-Omics and AI-Based Precision Medicine Framework for Lung Adenocarcinoma (LUAD)

## 1. Project Overview

Lung adenocarcinoma (LUAD) is a molecularly heterogeneous subtype of non-small cell lung cancer characterized by complex genomic, transcriptomic and epigenetic alterations.

This research project aims to develop an integrated multi-omics and artificial intelligence-based precision medicine framework for personalized drug response prediction in LUAD.

The study combines transcriptomic, mutational, epigenetic, clinical and pharmacogenomic information to investigate molecular mechanisms associated with LUAD progression, identify potential biomarkers and explore therapeutic response patterns.

By integrating publicly available cancer datasets with computational biology and machine learning approaches, this project seeks to establish a reproducible framework for molecular characterization, biomarker discovery, therapeutic prioritization and personalized drug response prediction.

## 2. Research Objectives

The major objectives of this research are:

1. Identify differentially expressed genes associated with lung adenocarcinoma through transcriptomic analysis.
2. Investigate biological processes, molecular functions and pathways associated with disease progression.
3. Characterize genomic alterations and mutation profiles in LUAD.
4. Investigate DNA methylation patterns and their potential regulatory associations with gene expression.
5. Integrate multiple molecular data modalities to identify candidate biomarkers.
6. Investigate immune infiltration and tumor microenvironment characteristics.
7. Explore drug-response biomarkers using pharmacogenomic resources.
8. Investigate the transferability of drug-response signatures between pharmacogenomic datasets and TCGA-LUAD.
9. Develop machine learning models for drug-response prediction.
10. Evaluate model performance and identify potentially relevant therapeutic candidates.
11. Investigate the prognostic relevance of candidate biomarkers through survival analysis.
12. Validate important molecular findings using independent gene-expression datasets.

## 3. Study Datasets and Resources

The project utilizes publicly available datasets and established bioinformatics resources.

| Dataset / Resource | Application |
|---|---|
| TCGA-LUAD | Transcriptomic, clinical, mutation and methylation characterization |
| GEO GSE68465 | Independent gene-expression validation |
| GEO GSE72094 | Independent gene-expression validation |
| GDSC | Drug sensitivity and pharmacogenomic analysis |
| CTRP | Drug-response and pharmacogenomic analysis |

Additional information regarding dataset accession numbers, sample characteristics, data formats, inclusion criteria and processing procedures will be maintained in:

`docs/dataset_inventory.md`

All datasets must be cited according to their original publications and database requirements.

## 4. Overall Research Workflow

The research framework is organized into the following analytical stages:

### Stage 1: Data Acquisition and Validation
- Public dataset identification and retrieval.
- Sample metadata collection.
- Data quality assessment.
- Patient-level data reconciliation.
- Verification of sample and clinical information.

### Stage 2: Transcriptomic Analysis
- RNA-seq data processing.
- Quality control and normalization.
- Differential gene expression analysis.
- Identification of upregulated and downregulated genes.

### Stage 3: Genomic and Epigenetic Characterization
- Somatic mutation profiling.
- Mutation quality control.
- DNA methylation analysis.
- Investigation of potential epigenetic regulation.

### Stage 4: Functional and Biological Characterization
- Gene Ontology enrichment.
- KEGG and Reactome pathway analysis.
- Protein-protein interaction analysis.
- Candidate biomarker prioritization.

### Stage 5: Tumor Microenvironment Analysis
- Immune infiltration estimation.
- Tumor microenvironment characterization.
- Investigation of relationships between molecular signatures and immune-associated features.

### Stage 6: Multi-Omics Integration
- Integration of transcriptomic, mutational and methylation information.
- Identification of cross-modal molecular associations.
- Prioritization of candidate biomarkers.
- Investigation of molecular patterns associated with LUAD.

### Stage 7: Drug Response and Pharmacogenomic Analysis
- GDSC and CTRP drug-response analysis.
- Biomarker transfer and evaluation.
- Investigation of drug sensitivity associations.
- Therapeutic candidate prioritization.

### Stage 8: Machine Learning
- Feature selection.
- Model development.
- Drug-response prediction.
- Model evaluation and performance comparison.
- Interpretation of predictive features.

### Stage 9: Clinical and Independent Validation
- Survival analysis.
- Prognostic biomarker investigation.
- Independent GEO dataset validation.
- Integrated interpretation of findings.

## 5. Repository Organization

The repository is structured into independent analytical modules to support organized development, reproducibility and integration.

```text
LUAD-MultiOmics-PrecisionMedicine/
│
├── README.md
├── LICENSE
├── CITATION.cff
├── .gitignore
│
├── docs/
│   ├── project_overview.md
│   ├── research_objectives.md
│   ├── study_design.md
│   ├── dataset_inventory.md
│   ├── methodology.md
│   └── progress_and_milestones.md
│
├── data/
│   ├── README.md
│   ├── metadata/
│   ├── processed/
│   └── external_references/
│
├── 01_RNAseq_Analysis/
│   ├── scripts/
│   ├── results/
│   └── README.md
│
├── 02_Mutation_Analysis/
│   ├── scripts/
│   ├── results/
│   └── README.md
│
├── 03_Methylation_Analysis/
│   ├── scripts/
│   ├── results/
│   └── README.md
│
├── 04_TCGA_Data_Validation/
│   ├── scripts/
│   ├── reports/
│   ├── validation_tables/
│   └── README.md
│
├── 05_Functional_Enrichment/
│   ├── scripts/
│   ├── results/
│   └── README.md
│
├── 06_Immune_Infiltration/
│   ├── scripts/
│   ├── results/
│   └── README.md
│
├── 07_MultiOmics_Integration/
│   ├── scripts/
│   ├── results/
│   └── README.md
│
├── 08_GDSC_CTRP_Drug_Response/
│   ├── biomarker_transfer/
│   ├── drug_sensitivity/
│   ├── scripts/
│   └── README.md
│
├── 09_Machine_Learning/
│   ├── scripts/
│   ├── models/
│   ├── predictions/
│   ├── evaluation/
│   └── README.md
│
├── 10_Survival_Analysis/
│   ├── scripts/
│   ├── results/
│   └── README.md
│
├── 11_GEO_Validation/
│   ├── GSE68465/
│   ├── GSE72094/
│   └── README.md
│
├── manuscript/
│   ├── figures/
│   ├── tables/
│   └── references/
│
└── environment/
    ├── requirements.txt
    └── environment.yml
```

Each analytical module should maintain its own scripts, relevant outputs and module-specific documentation.

## 6. Reproducibility and Documentation Standards

Reproducibility is a fundamental requirement of this research project.

All analytical contributions must follow these standards:

- Maintain organized and clearly named scripts.
- Document original data sources and accession numbers.
- Specify input file formats and expected directory structures.
- Record software, package versions and computational dependencies.
- Provide clear execution instructions.
- Document preprocessing, normalization and filtering procedures.
- Record sample inclusion and exclusion criteria.
- Maintain quality-control reports and intermediate validation records.
- Clearly distinguish exploratory results from validated findings.
- Preserve original scripts and document subsequent modifications.
- Ensure that reported results can be traced to their corresponding analytical workflows.

### Module-Specific README Requirements

Every major analysis directory must contain a README file covering:

1. Purpose of the analysis.
2. Dataset and input file information.
3. Software and dependencies.
4. Execution instructions.
5. Description of generated outputs.
6. Quality-control procedures.
7. Limitations and important observations.

## 7. Data Management and Sharing Policy

This repository is intended to maintain research scripts, documentation, metadata templates, selected processed outputs and computational reports.

The following guidelines must be followed:

- Do not upload restricted or controlled-access datasets.
- Do not upload identifiable or sensitive patient-level information.
- Do not upload large raw sequencing files such as FASTQ, BAM or CRAM files.
- Avoid committing unnecessarily large intermediate matrices and model artifacts.
- Use public database accession numbers and reproducible download procedures wherever possible.
- Verify database and publication data-sharing conditions before uploading files.
- Document external data locations and retrieval procedures.
- Keep local datasets and sensitive configuration files outside the public repository.

Large datasets and files that exceed GitHub's practical storage limits should be maintained in appropriate approved data repositories, with references documented in the project.

## 8. Project Progress and Updates

The repository will be updated progressively as individual analytical modules are developed, evaluated and integrated.

The current research framework includes:

- TCGA-LUAD data validation and patient-level reconciliation.
- Transcriptomic and multi-omics analysis planning.
- Pharmacogenomic drug-response investigation.
- Biomarker transfer analysis.
- Development of machine learning-based drug-response prediction workflows.

Further progress, completed analyses, validation findings and outstanding tasks will be documented in:

`docs/progress_and_milestones.md`

The completion of an individual analytical module does not imply completion or validation of the overall research framework.

## 9. Contribution and Review Guidelines

All contributions should follow a structured version-control workflow.

- Each analytical module should be maintained within its designated directory.
- Contributors should use separate development branches for substantial changes.
- Changes should be submitted through pull requests.
- Scripts and outputs should be reviewed before integration into the main branch.
- Documentation should accompany new analytical workflows.
- Major methodological changes should be recorded.
- The main branch should contain reviewed and organized project contributions.

This approach helps maintain consistency, transparency and reproducibility across the research project.

## 10. Software and Computational Environment

The project may use a combination of bioinformatics, statistical computing and machine learning tools.

The software environment and package dependencies will be documented in:

- `environment/requirements.txt`
- `environment/environment.yml`

Individual modules must specify any additional software or specialized dependencies required for execution.

## 11. Citation and Acknowledgement

All datasets, databases, software tools and analytical resources used in this research must be cited according to their original publications and usage guidelines.

Once the associated research manuscript is published, the repository citation information will be updated accordingly.

## 12. Disclaimer

This repository is intended exclusively for academic research and computational investigation.

The analyses, biomarkers and predictive models developed through this project represent research findings and are not intended for direct clinical diagnosis, treatment selection or replacement of professional medical decision-making.

---

**Research Area:** Lung Adenocarcinoma (LUAD)

**Research Focus:** Multi-Omics Integration | Biomarker Discovery | Pharmacogenomics | Drug Response Prediction | Machine Learning | Precision Medicine

**Repository Purpose:** Centralized research documentation, computational workflows, analytical outputs and reproducible scientific investigation.
